Mapping RNA biomarkers in individual tumour cells while preserving tissue context
RNA biomarkers help inform cancer therapy choices, but measuring them in clinical laboratories remains difficult. Existing analysis methods can provide insufficient information or require costly, complex equipment and workflows, limiting their practical use.
2NA FISH develops probes and analysis software to map RNA biomarkers in individual cells within tissue. Its platform works with standard fluorescence microscopes for translational oncology research and biomarker studies.
What stands out about 2NA FISH
Announced additional pre-seed funding in January 2026, led by GF BRYCK Ventures with follow-on investment from Twip.
The founding project received an EXIST Forschungstransfer grant, documented in a TUM-hosted project recruitment brief.
Won the Munich Startup Award 2024 at the Munich Startup Festival.
Co-founder Christina Port has a PhD in molecular biology and expertise in nanotechnology and fluorescent probe design.
Historical co-founder Johannes Breulmann said he sold his previous startup, InsureQ, before joining 2NA FISH.
Christina Port described support from the TUM Incubator in a 2024 interview with Munich Startup.
LMU Research Services reported a €75,000 Women TechEU grant for 2NA FISH following its selection in Call 4.
LMU Research Services identifies 2NA FISH as an LMU spin-off in its Women TechEU award announcement.
The founding project won the Medical Valley Award, as documented in its TUM-hosted recruitment brief.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.